Sort
40,608 grants matching “prostate cancer”
DEVELOPMENT OF PSCA-TARGETED MINIBODIES FOR IMAGING OF PROSTATE CANCER
$1,146,628University Of California, Los Angeles · · FY2008 · Department of Defense
A PRECISION MEDICINE STUDY OF HOW INFLAMMATION MAY UNDERLIE THE EXCESSIVE BURDEN OF PROSTATE CANCER IN MEN OF AFRICAN ANCESTRY
$1,146,586Tuskegee University · · FY2018 · Department of the Army
CHARACTERIZING THE ROLES OF ALTERNATIVE POLYADENYLATION DURING PROSTATE CANCER PROGRESSION.
$1,146,045Oregon Health & Science University · · FY2021 · Defense Health Agency
ROCKY MOUNTAIN CANCER GENETICS COALITION
$1,145,638University Of Utah · U24 · FY2003 · CA
Integrative Molecular Epidemiology of Human Cancer
$1,145,460Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Biomarkers in Cancer Diagnosis, Prognosis and Therapeutic Outcome
$1,145,460Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
EARLY DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING ULTRASONIC ACOUSTIC RADIATION FORCE IMPULSE (ARFI) IMAGING
$1,145,431Duke University · · FY2016 · Department of the Army
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
$1,145,283Mariana C Stern · University Of Southern California · U54 · FY2023 · CA
Development of a novel PET imaging agent for prostate cancer
$1,145,108Beatrice Langton-Webster · Cancer Targeted Technology, Llc · R44 · FY2011 · CA
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
$1,144,955Andrea Califano · Columbia University Health Sciences · U01 · FY2019 · CA
MOUSE MODELS FOR HUMAN PROSTATE CANCER
$1,144,549University Of California Los Angeles · U01 · FY2003 · CA
TARGETING BRD9 IN TREATMENT-RESISTANT PROSTATE CANCER
$1,144,362Purdue University · · FY2022 · Department of the Army
1/2 Cancer Research and Education to Advance HealTh Equity (CREATE) Partnership
$1,143,914Hala Madanat · San Diego State University · U54 · FY2024 · CA
Animal Model and Genotyping Core Support Facility
$1,143,457Wendy Du Bois De Vroylande · Division Of Basic Sciences - Nci · ZIC · FY2019 · CA
(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and Treatment
$1,143,340John V Frangioni · Curadel, Llc · R01 · FY2015 · CA
Center for Advanced Imaging Innovation and Research (CAI2R)
$1,143,323Daniel K Sodickson · New York University School Of Medicine · P41 · FY2017 · EB
ANTI-ANDROGENS TREATMENT ENHANCES CYTOTOXICITY OF OXIDATIVE- PHOSPHORYLATION INHIBITORS AGAINST CASTRATION-RESISTANT PROSTATE CANCER
$1,143,016The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2020 · Defense Health Agency
DATA SCIENCE APPROACHES TO PREDICT AND UNDERSTAND SIDE EFFECTS OF ANDROGEN DEPRIVATION THERAPY IN VETERANS WITH PROSTATE CANCER UNDERGOING LONG- TERM TREATMENT.
$1,142,336The Trustees Of Columbia University In The City Of New York · · FY2025 · Defense Health Agency
1/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership
$1,142,009Brian M. Rivers · Morehouse School Of Medicine · U54 · FY2022 · CA
POPULATION-BASED IDENTIFICATION OF PROSTATE CANCER
$1,141,800University Of Utah · · FY2018 · Defense Health Agency
Targeting apoptotic cells to enhance radiotherapy
$1,141,784Jianghong Rao · Stanford University · R01 · FY2025 · CA
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors
$1,141,669D. Martin Watterson · Northwestern University At Chicago · U01 · FY2014 · AG
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
$1,141,254John David Carpten · University Of Southern California · U54 · FY2020 · CA
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
$1,141,251John David Carpten · University Of Southern California · U54 · FY2021 · CA
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
$1,141,251John David Carpten · University Of Southern California · U54 · FY2018 · CA